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Abstract
Background: Emerging evidence suggests that ataxia telangiectasia-mutated (ATM) is involved in numerous
damage repair signaling pathways and cell-cycle checkpoints. Heterozygous carriers of ATM-mutations have an
increased risk for the development of breast cancer. The purpose of this study is to evaluate the association
between ATM exon39 5557G > A (D1853N, rs1801516) polymorphism and breast cancer susceptibility with the use
of a meta-analysis.
Methods: By searching PubMed and Embase databases, a total of 9 epidemiological studies with 4,191 cases and
3,780 controls were identified. Crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for
ATM D1853N polymorphism and breast cancer risk were calculated using fixed- or random-effects model based on
the degree of heterogeneity among studies.
Results: No significant association between the ATM D1853N polymorphism and breast cancer risk was observed
in overall analysis (GA versus GG: OR = 1.18; 95% CI, 0.90-1.53; AA versus GG: OR = 0.77; 95% CI, 0.58-1.03;
dominant model: OR = 1.16; 95% CI, 0.89-1.51; and recessive model: OR = 0.78; 95% CI, 0.59-1.04, respectively).
Conclusion: Our results indicate that ATM D1853N polymorphism is not a risk factor for developing breast cancer.
Background
Ataxia-telangiectasia (A-T) is an autosomal recessive
disorder that affects many parts of the body and leads
to increased risk of malignancy, including breast cancer
[1-3]. A-T is caused by mutations in the ataxia telan-
giectasia-mutated (ATM)[ 4 ] .A T M ,am e m b e ro ft h e
phosphatidylinositol 3-kinase-like family, plays central
roles in the repair of DNA double-strand breaks that
was caused by a range of DNA-damaging agents such as
ionizing radiation [5].
The ATM gene, located on chromosome 11q22-23
and consisting of 66 exons, has been reported to be
involved in numerous damage repair signaling pathways
and cell-cycle checkpoints [4,6]. Loss of heterozygosity
in the region of the ATM gene has been detected in
approximately 40% of human sporadic breast tumors
[7-11]. Breast cancer patients with the combination of
radiation treatment and an ATM missense variant
resulted in a shorter mean interval to develop a second
tumor than patients without radiation treatment and
ATM germline mutation [12]. Previously, some studies
reported that female ATM-heterozygous carriers have
an increased risk of breast cancer [1,13-18]. In contrast,
some studies failed to find that ATM-heterozygous
mutations were more frequent in breast cancer cases.
Recently, Mehdipour et al. reported that a common
single nucleotide polymorphism ATM exon39 5557G >
A (D1853N, rs1801516) may be considered as a predis-
position factor for developing breast cancer, especially
in cancer-prone pedigrees [19]. To date, a number of
studies have been performed to investigate the associa-
tion between the ATM D1853N polymorphism and
breast cancer risk, but the evidence regarding the role of
ATM as a genetic marker for breast cancer is
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estimating the association, a meta-analysis was
performed.
Materials and methods
Eligible studies and data extraction
We searched the articles using the following terms
“ATM“ and “breast cancer” and “polymorphism” or “var-
iant” in PubMed and Embase databases (last search: 31
May, 2010). Additionally, we checked all relevant publi-
cations to retrieve the most eligible literatures.
The inclusion criteria were used for the literature
selection: (a) articles about ATM D1853N polymorphism
and breast cancer risk; (b) case-control studies; (c) suffi-
cient published data for calculating odds ratios (ORs)
and their corresponding 95% confidence intervals (95%
CIs). The following information was collected indepen-
dently by two investigators (Gao LB and Pan XM) from
each study: first author’s surname, year of publication,
country, ethnicity, number of cases and controls with
various genotypes, genotyping techniques, quality con-
trol for the genotyping methods, Hardy-Weinberg equi-
librium (HWE) and minor allele frequency (MAF) in
controls (Table 1).
Statistical analysis
The process of meta-analysis in the current study was
performed as described previously in detail [20-22]. In
brief, crude ORs and corresponding 95% CIs were pre-
formed to assess the association between ATM D1853N
polymorphism and breast cancer risk. The pooled ORs
were calculated for heterozygote comparison (GA versus
GG), homozygote comparison (AA versus GG), domi-
nant model (GA/AA versus GG) and recessive model
(AA versus GA/GG), respectively. The statistical hetero-
geneity among studies was checked by Q-test and I
2 sta-
tistics [23]. If the P value greater than 0.10 for Q-test,
indicating absence of heterogeneity, the fixed-effects
model (the Mantel-Haenszel method) was used to calcu-
late the pooled OR [24]; otherwise, the random-effects
model (the DerSimonian and Laird method) was used
[25]. Publication bias of literatures was estimated using
Begg’s funnel plot [26]. All statistical analyses were car-
ried out with STATA software, version 10.0 (STATA
Corp., College Station, TX).
Results
Characteristics of studies
Overall, nine studies involving 4,191 cases and 3,780
controls about ATM D1853N polymorphism and breast
cancer susceptibility were available for this meta-analy-
sis. The main characteristics of eligible studies are sum-
marized in Table 1. There were six studies of European
populations, two studies of South American populations,
and one study of mixed population that included more
than one ethnic descent. Several genotyping methods
were used, including polymerase chain reaction-restric-
tion fragment length polymorphism (PCR-RFLP), dena-
tured high performance liquid chromatography
(DHPLC), allele-specific oligonucleotide (ASO), PCR-
single strand conformation polymorphism (PCR-SSCP),
conformation sensitive gel electrophoresis (CSGE), Taq-
Man, and sequencing. Approximately 67% (6/9) of these
studies described quality control for the genotyping
assay. The genotype distributions in the controls of all
studies were consistent with Hardy-Weinberg equili-
brium except for one study [27].
Main results
The main results of this meta-analysis are shown in
Table 2. Overall, no significant association between the
ATM D1853N polymorphism and breast cancer risk was
observed. After subgroup analyses according to ethni-
city, significantly increased risk was observed in South
Table 1 Characteristics of literatures included in the meta-analysis
References Year Country Ethnicity Genotype distribution HWE (controls) MAF
case control
GG GA AA GG GA AA
Angele [30] 2003 France European 192 56 6 240 65 7 Yes 0.13
Buchholz [31] 2004 USA Mixed 39 17 2 394 119 15 Yes 0.14
Dork [32] 2001 Germany European 753 235 12 422 74 4 Yes 0.08
Gonzalez-Hormazabal [29] 2008 Chile South American 100 26 0 174 26 0 Yes 0.07
Heikkinen [33] 2005 Finland European 68 44 9 174 109 23 Yes 0.25
Renwick [34] 2006 UK European 339 98 6 371 131 19 Yes 0.16
Schrauder [35] 2008 Germany European 406 99 9 369 129 13 Yes 0.15
Tapia [27] 2008 Chile South American 74 19 1 183 15 2 No 0.05
Tommiska [36] 2006 Finland European 954 561 66 404 260 38 Yes 0.24
HWE, Hardy-Weinberg equilibrium
MAF, minor allele frequency
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Page 2 of 5American population (GA versus GG: OR = 2.19; 95%
CI, 1.38-3.47; and dominant model: OR = 2.15; 95% CI,
1.37-3.38, respectively) but not in European and mixed
populations.
Publication bias
Begg’s funnel plot was used to identify the potential
publication bias of literatures on breast cancer, and the
results did not show any evidence of publication bias in
any comparison model (P > 0.05).
Discussion
Previous studies have inconclusive results about the
association between ATM D1853N polymorphism and
breast cancer risk, which might be caused by relatively
small sample size in a single study. Meta-analysis offers
a rational and helpful way to solve this practical pro-
blem by combination the findings from independent
studies. In the current meta-analysis, we cumulated the
data from nine case-control studies to explore the asso-
ciation between ATM D1853N polymorphism and
breast cancer risk. No significant association between
this polymorphism and breast cancer risk was observed
in the overall study populations. Our result was consis-
tent with the finding from a previous meta-analysis
showing that another polymorphism of ATM (S49C,
rs1800054) was not significantly associated with breast
cancer susceptibility [28]. This finding indicates that the
ATM D1853N polymorphism is not a risk factor for
developing breast cancer, although a significantly
increased risk of breast cancer in ATM-heterozygous
carriers has been reported [1,13-18].
After subgroup analyses according to ethnicity, we
found that the ATM D1853N polymorphism was asso-
ciated with a significantly increased risk of breast cancer
in South American population (heterozygote comparison
and dominant model) but not in European and mixed
populations. The reason for these discrepancies is not
very clear. There are, however, some possible reasons.
Firstly, the ATM D1853N polymorphism may present
with different frequencies in different populations and
as a result may be associated with different degrees of
breast cancer risk among different ethnic populations.
Secondly, the genotype distribution in the controls of a
South American study was departed from Hardy-Wein-
berg equilibrium [27], indicating that there was a high
risk of selection bias because the controls may not be
representative of the general population very well.
Thirdly, the positive association might have occurred by
chance due to the insufficient statistical power with only
two South American studies eligible in this meta-analy-
sis [27,29]. Therefore, additional studies with larger
sample size are of great importance to clarify this
finding.
Some limitations of this meta-analysis should be taken
into consideration. On the one hand, the numbers of
cases and controls analyzed for D1853N (rs1801516)
found in the literature is still very small and might not
precisely answer the given question. Especially, for some
subgroup analyses, the statistical power is so low that
caution should be taken in interpreting these results,
even though positive association was found in South
American population. On the other hand, data were not
stratified by age at menarche, number of full-term preg-
nancies, menopausal status, and other suspected factors
due to absence of available information.
In conclusion, the overall outcomes of this meta-ana-
lysis have shown that the ATM D1853N polymorphism
is not associated with breast cancer risk, indicating that
this polymorphism is not an independent risk factor for
the development of breast cancer. Well-designed,
unbiased studies with a wider spectrum of subjects
should be of great value to explore other potential risk
factors.
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Table 2 Main results of pooled ORs in the meta-analysis
n
a Cases/controls GA versus GG AA versus GG GA/AA versus GG
(dominant)
AA versus GA/GG
(recessive)
OR (95%CI) P
b OR (95%CI) P
b OR (95%CI) P
b OR (95%CI) P
b
Total 9 4,191/3,780 1.18 (0.90-1.53) < 0.001 0.77 (0.58-1.03) 0.50 1.16 (0.89-1.51) < 0.001 0.78 (0.59-1.04) 0.66
Ethnicity
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b P value of Q-test for heterogeneity test. Random-effects model was used if the P value <0.10; otherwise, fixed-effects model was used
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